vs
CoStar Group（CSGP）与Pediatrix Medical Group, Inc.（MD）财务数据对比。点击上方公司名可切换其他公司
CoStar Group的季度营收约是Pediatrix Medical Group, Inc.的1.8倍（$899.9M vs $493.8M），Pediatrix Medical Group, Inc.净利率更高（6.8% vs 5.2%，领先1.7%），CoStar Group同比增速更快（26.9% vs -1.7%），过去两年CoStar Group的营收复合增速更高（17.1% vs -0.1%）
CoStar Group是1987年成立的美国商业地产服务商，总部位于弗吉尼亚州阿灵顿，业务覆盖北美、欧洲地区，为商业地产行业提供信息、分析及营销解决方案，旗下运营CoStar线上数据库、新闻网站及Apartments.com、Homes.com等多个线上平台。
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
CSGP vs MD — 直观对比
营收规模更大
CSGP
是对方的1.8倍
$493.8M
营收增速更快
CSGP
高出28.6%
-1.7%
净利率更高
MD
高出1.7%
5.2%
两年增速更快
CSGP
近两年复合增速
-0.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $899.9M | $493.8M |
| 净利润 | $46.5M | $33.7M |
| 毛利率 | 78.6% | — |
| 营业利润率 | 5.5% | 9.9% |
| 净利率 | 5.2% | 6.8% |
| 营收同比 | 26.9% | -1.7% |
| 净利润同比 | -22.2% | 10.5% |
| 每股收益（稀释后） | $0.12 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGPMD
| Q4 25 | $899.9M | $493.8M | ||
| Q3 25 | $833.6M | $492.9M | ||
| Q2 25 | $781.3M | $468.8M | ||
| Q1 25 | $732.2M | $458.4M | ||
| Q4 24 | $709.4M | $502.4M | ||
| Q3 24 | $692.6M | $511.2M | ||
| Q2 24 | $677.8M | $504.3M | ||
| Q1 24 | $656.4M | $495.1M |
净利润CSGPMD
| Q4 25 | $46.5M | $33.7M | ||
| Q3 25 | $-30.9M | $71.7M | ||
| Q2 25 | $6.2M | $39.3M | ||
| Q1 25 | $-14.8M | $20.7M | ||
| Q4 24 | $59.8M | $30.5M | ||
| Q3 24 | $53.0M | $19.4M | ||
| Q2 24 | $19.2M | $-153.0M | ||
| Q1 24 | $6.7M | $4.0M |
毛利率CSGPMD
| Q4 25 | 78.6% | — | ||
| Q3 25 | 79.3% | — | ||
| Q2 25 | 78.5% | — | ||
| Q1 25 | 79.1% | — | ||
| Q4 24 | 80.1% | — | ||
| Q3 24 | 79.7% | — | ||
| Q2 24 | 80.0% | — | ||
| Q1 24 | 78.5% | — |
营业利润率CSGPMD
| Q4 25 | 5.5% | 9.9% | ||
| Q3 25 | -6.1% | 13.8% | ||
| Q2 25 | -3.5% | 12.8% | ||
| Q1 25 | -5.8% | 7.0% | ||
| Q4 24 | 5.6% | 7.8% | ||
| Q3 24 | 3.4% | 6.6% | ||
| Q2 24 | -2.4% | -31.3% | ||
| Q1 24 | -6.5% | 3.2% |
净利率CSGPMD
| Q4 25 | 5.2% | 6.8% | ||
| Q3 25 | -3.7% | 14.5% | ||
| Q2 25 | 0.8% | 8.4% | ||
| Q1 25 | -2.0% | 4.5% | ||
| Q4 24 | 8.4% | 6.1% | ||
| Q3 24 | 7.7% | 3.8% | ||
| Q2 24 | 2.8% | -30.3% | ||
| Q1 24 | 1.0% | 0.8% |
每股收益（稀释后）CSGPMD
| Q4 25 | $0.12 | $0.40 | ||
| Q3 25 | $-0.07 | $0.84 | ||
| Q2 25 | $0.01 | $0.46 | ||
| Q1 25 | $-0.04 | $0.24 | ||
| Q4 24 | $0.14 | $0.37 | ||
| Q3 24 | $0.13 | $0.23 | ||
| Q2 24 | $0.05 | $-1.84 | ||
| Q1 24 | $0.02 | $0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6B | $375.2M |
| 总债务越低越好 | $140.0M | $570.5M |
| 股东权益账面价值 | $8.3B | $865.9M |
| 总资产 | $10.5B | $2.2B |
| 负债/权益比越低杠杆越低 | 0.02× | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资CSGPMD
| Q4 25 | $1.6B | $375.2M | ||
| Q3 25 | $1.9B | $340.1M | ||
| Q2 25 | $3.6B | $224.7M | ||
| Q1 25 | $3.7B | $99.0M | ||
| Q4 24 | $4.7B | $229.9M | ||
| Q3 24 | — | $103.8M | ||
| Q2 24 | — | $19.4M | ||
| Q1 24 | — | $8.0M |
总债务CSGPMD
| Q4 25 | $140.0M | $570.5M | ||
| Q3 25 | $1.0B | $577.2M | ||
| Q2 25 | $1.0B | $583.9M | ||
| Q1 25 | $1.0B | $590.5M | ||
| Q4 24 | $1.0B | $597.1M | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $1.0B | — |
股东权益CSGPMD
| Q4 25 | $8.3B | $865.9M | ||
| Q3 25 | $8.6B | $890.7M | ||
| Q2 25 | $8.6B | $833.8M | ||
| Q1 25 | $8.6B | $789.2M | ||
| Q4 24 | $7.6B | $764.9M | ||
| Q3 24 | $7.5B | $732.5M | ||
| Q2 24 | $7.4B | $706.5M | ||
| Q1 24 | $7.3B | $856.2M |
总资产CSGPMD
| Q4 25 | $10.5B | $2.2B | ||
| Q3 25 | $10.8B | $2.2B | ||
| Q2 25 | $10.5B | $2.1B | ||
| Q1 25 | $10.4B | $2.0B | ||
| Q4 24 | $9.3B | $2.2B | ||
| Q3 24 | $9.1B | $2.1B | ||
| Q2 24 | $9.1B | $2.0B | ||
| Q1 24 | $9.0B | $2.2B |
负债/权益比CSGPMD
| Q4 25 | 0.02× | 0.66× | ||
| Q3 25 | 0.12× | 0.65× | ||
| Q2 25 | 0.12× | 0.70× | ||
| Q1 25 | 0.12× | 0.75× | ||
| Q4 24 | 0.13× | 0.78× | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $162.1M | $114.1M |
| 自由现金流经营现金流 - 资本支出 | $101.3M | — |
| 自由现金流率自由现金流/营收 | 11.3% | — |
| 资本支出强度资本支出/营收 | 6.8% | — |
| 现金转化率经营现金流/净利润 | 3.49× | 3.39× |
| 过去12个月自由现金流最近4个季度 | $123.0M | — |
8季度趋势，按日历期对齐
经营现金流CSGPMD
| Q4 25 | $162.1M | $114.1M | ||
| Q3 25 | $68.2M | $137.3M | ||
| Q2 25 | $146.5M | $137.2M | ||
| Q1 25 | $53.2M | $-117.5M | ||
| Q4 24 | $94.6M | $133.0M | ||
| Q3 24 | $100.3M | $91.8M | ||
| Q2 24 | $58.1M | $107.0M | ||
| Q1 24 | $139.6M | $-125.2M |
自由现金流CSGPMD
| Q4 25 | $101.3M | — | ||
| Q3 25 | $-5.5M | — | ||
| Q2 25 | $27.7M | — | ||
| Q1 25 | $-500.0K | — | ||
| Q4 24 | $25.2M | — | ||
| Q3 24 | $40.2M | — | ||
| Q2 24 | $-14.7M | — | ||
| Q1 24 | $-237.1M | — |
自由现金流率CSGPMD
| Q4 25 | 11.3% | — | ||
| Q3 25 | -0.7% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 3.6% | — | ||
| Q3 24 | 5.8% | — | ||
| Q2 24 | -2.2% | — | ||
| Q1 24 | -36.1% | — |
资本支出强度CSGPMD
| Q4 25 | 6.8% | — | ||
| Q3 25 | 8.8% | — | ||
| Q2 25 | 15.2% | — | ||
| Q1 25 | 7.3% | — | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | 8.7% | — | ||
| Q2 24 | 10.7% | — | ||
| Q1 24 | 57.4% | — |
现金转化率CSGPMD
| Q4 25 | 3.49× | 3.39× | ||
| Q3 25 | — | 1.91× | ||
| Q2 25 | 23.63× | 3.49× | ||
| Q1 25 | — | -5.66× | ||
| Q4 24 | 1.58× | 4.36× | ||
| Q3 24 | 1.89× | 4.72× | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 20.84× | -31.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGP
| Co Star | $503.8M | 56% |
| Other | $283.0M | 31% |
| Loop Net | $94.7M | 11% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
